How should I manage a patient with recurrent moderate major depressive disorder (F33.1) and generalized anxiety disorder (F41.1) who is currently taking citalopram 40 mg daily, was discontinued from aripiprazole (Abilify) due to extrapyramidal symptoms, and is now on bupropion 150 mg daily but complains of anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Discontinue Bupropion and Optimize Citalopram Monotherapy

Given that bupropion is known to exacerbate anxiety symptoms—particularly at initiation and in patients with comorbid generalized anxiety disorder—you should discontinue the bupropion and continue citalopram 40 mg daily as monotherapy for this patient with recurrent moderate MDD and GAD. 1

Rationale for Discontinuing Bupropion

The FDA labeling for bupropion explicitly warns that patients should be instructed to contact healthcare professionals if they experience anxiety, agitation, panic attacks, insomnia, irritability, hostility, or aggressiveness, especially early during treatment 1. Your patient is complaining of anxiety while on bupropion 150 mg daily—this is a recognized adverse effect, not a therapeutic failure of the SSRI.

While recent meta-analyses suggest bupropion may have comparable anxiolytic efficacy to SSRIs when anxiety is measured as a secondary outcome in depression trials 2, these findings apply to anxiety symptoms of depression, not to patients with a primary diagnosis of generalized anxiety disorder. The 2025 systematic review acknowledges that SSRIs showed a modest advantage over bupropion in patients with high baseline anxiety 3, which describes your patient.

Why Citalopram Monotherapy is Appropriate

  • Citalopram 40 mg is already at the maximum FDA-approved dose due to QT prolongation risk 4
  • Citalopram has demonstrated efficacy for both MDD and GAD 4
  • The patient was presumably stable on citalopram before bupropion was added
  • Second-generation antidepressants show no clinically significant differences in efficacy for treating MDD 5

Management Algorithm

Week 0-2 (Immediate):

  • Discontinue bupropion 150 mg daily immediately (no taper needed at this low dose)
  • Continue citalopram 40 mg daily
  • Monitor closely for anxiety symptoms within 1-2 weeks 5

Week 2-8:

  • Assess therapeutic response and anxiety levels every 1-2 weeks 5
  • If anxiety improves but depression persists after 6-8 weeks, consider switching to a different SSRI or SNRI rather than adding bupropion back 5

If Inadequate Response at 6-8 Weeks:

  • Switch to escitalopram (10-20 mg daily)—it has the least effect on CYP450 enzymes and lower propensity for drug interactions compared to other SSRIs 4
  • Switch to sertraline (50-200 mg daily)—well-tolerated with less effect on metabolism of other medications 6
  • Switch to duloxetine (60 mg daily)—effective for both MDD and generalized anxiety disorder 7

Critical Pitfalls to Avoid

Do not add bupropion back to citalopram. While combination therapy with citalopram plus bupropion has shown higher remission rates than monotherapy in treatment-resistant depression 8, 9, this strategy is appropriate for patients who have failed to respond to adequate SSRI monotherapy, not for patients experiencing anxiety exacerbation from bupropion. Your patient's complaint of anxiety while on bupropion indicates poor tolerability, not treatment resistance.

Do not interpret the anxiety as "breakthrough GAD." The temporal relationship—anxiety complaints emerging after bupropion initiation—strongly suggests a medication-induced effect rather than inadequate treatment of the underlying anxiety disorder.

Monitor for serotonin syndrome if you later consider adding any serotonergic agent, though this risk is low with citalopram monotherapy 4.

Alternative Augmentation Strategies (If Needed Later)

If the patient fails to achieve remission on optimized SSRI monotherapy after 6-8 weeks, evidence-based second-step options include:

  • Switching to another SSRI or SNRI (preferred over augmentation for first inadequate response) 10, 11
  • Adding cognitive behavioral therapy (combination CBT + SSRI shows superior outcomes to either alone for anxiety disorders) 4
  • Augmentation with mirtazapine (15-30 mg at bedtime)—addresses both depression and anxiety, promotes sleep 6

Avoid antipsychotic augmentation given this patient's history of extrapyramidal symptoms with aripiprazole. If augmentation with an antipsychotic is absolutely necessary in the future, quetiapine has lower EPS risk, but this should be a last-resort option 12.

References

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.